-
2022-502140-13-00
6
2023-01-11
Atrial fibrillation
Acute coronary syndrome
Chronic coronary syndrome
-
2023-503679-12-00
1
2022-11-21
Relapsed or Refractory Multiple Myeloma
-
2024-514180-25-00
5
2022-11-21
unresectable or metastatic HER2+ colorectal cancer
-
2023-504885-50-00
5
2022-11-07
Treatment of children with chronic kidney disease and proteinuria
-
2023-510384-36-00
5
2022-09-13
Newly Diagnosed Multiple Myeloma
-
2022-500311-39-00
6
2022-09-08
Patients with Crohn's disease undergoing surgery and having at least o
-
2023-503335-18-00
1
2022-07-29
Chronic myeloid leukemia
-
2022-501180-40-00
5
2022-06-17
Ewing Sarcoma
-
2023-503267-42-00
5
2022-06-10
Patients with a histological diagnosis of mismatch- repair deficient h
-
2023-506891-28-00
5
2022-05-02
The target population of interest in this study is participants with l
-
2024-516336-97-00
4
2022-02-21
METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
-
2024-510578-25-00
5
2021-11-05
Histologically proven high-risk medulloblastoma, with any of the curre
-
2023-505319-19-00
11
2021-09-01
Traumatic brain injury
-
2023-503435-17-00
5
2021-03-31
Juvenile psoriatic arthritis
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2023-507885-21-00
4
2020-08-18
Chronic Inflammatory Demyelinating Polyneuropathy
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2024-512321-84-00
5
2019-10-02
Patients after HSCT suffering from new or reactivated CMV or EBV or Ad
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2023-506857-40-00
5
2019-01-08
Prostate Cancer